$VRX Of the 25 tracked by Bloomberg, 18 still have buy ratings on Valeant shares. Another six rate the stock a hold, while only one, Dimitry Khmelnitsk at Veritas Investment Research, rates it a sell.
Lisa Hoppe 01:14 PM 10/22/2015
$VRX research #3 from Citron Research "Now Valeant has made new disclosures regarding its distribution channel, and they’ve led the company into a web of deception that … you have to read for yourselves." www.citronresearch.com/va...l-enron/
Lisa Hoppe 12:56 PM 10/03/2015
$VRX Citron Research published research #2 on Valeant "Investors, Politicians, and Concerned Citizens must note that Valeant raised the prices on the two key heart drugs in question the very next day after they acquired them … just to cover up for a bad quarter." www.citronresearch.com/ci...valeant/
David Lyons 12:01 PM 09/29/2015
$VRX heh... time to #sell the stocks don't recover at least for 6-12m after Citron research... or never recover!
Lisa Hoppe 11:36 AM 09/29/2015
$VRX BOOM... Citron Research published a research on Valeant. "As well as a major threat to the integrity of our entire healthcare system, Valeant (NYSE:VRX) is now the most devious three-cornered tax avoidance scheme we've ever seen." #sellwww.citronresearch.com/wh...granted/
John O'Donoghue 07:46 AM 08/21/2015
$VRX Valeant buys “female Viagra” maker Sprout but market is not aroused #bullish
Valeant Pharmaceuticals International, Inc. develops and distributes drugs. The Company develops drugs for unmet medical needs in central nervous system disorders; and distributes generic and branded generic drugs in Latin America and Eastern Europe.